Alto Neuroscience

balloon missed target pop arrows miss failure
Biotech

Boehringer's schizophrenia drug fails trio of phase 3 trials

Boehringer’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials.
Gabrielle Masson Jan 16, 2025 11:58am
failure crash no fail rocket cancelled end

Alto's midphase depression trial falls flat

Oct 23, 2024 4:47am
parasail Blue Lagoon parachute

CRISPR Tx, Novartis, Cour & more—Chutes & Ladders

May 24, 2024 8:30am
Graphic of an open door with the words exit above it

Biogen CMO heads for the exits

Mar 15, 2024 10:51am
Wall Street IPO initial public offering markets shares stock

Alto, Fractyl head to public markets with IPOs north of $100M

Feb 2, 2024 8:14am
Photo of Wall Street street sign with american flags in the background

Alto aims for $101M IPO to pave neuro development climb

Jan 30, 2024 11:37am